■ INTRODUCTION
Plant proteins are useful in the prevention of cardiovascular disease and diabetes. 1 In particular, some studies provided evidence that soy protein and/or peptides exert a hypoglycemic activity either in suitable animal models 2, 3 or in type-2 diabetic patients. 4, 5 Moreover, some peptides from soy protein improve glucose uptake in HepG2 cells 6 and peptide mixtures obtained by pepsin-pancreatin hydrolysis of soy protein improve glucose uptake in muscle L6 cells. 7 Other investigations support the hypoglycemic activity of lupin protein. 8, 9 In particular, it has been demonstrated that a specific lupin protein fraction decreases blood glucose concentration in rats 10 and has a relevant postprandial hypoglycemic effect in humans. 10 All these pieces of evidence suggest that the consumption of soy and lupin proteins may be beneficial for the prevention of type 2 diabetes.
Dipeptidyl peptidase IV (DPP-IV) is a new molecular target correlated with the development of type 2 diabetes. 11 It is a serine exopeptidase that cleaves Xaa-proline or Xaa-alanine dipeptides from the N-terminus of polypeptides. Among all DPP-IV substrates, the most widely investigated are glucagonlike peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two incretins playing essential roles in maintaining glucose homeostasis. 12, 13 Together, they stimulate the insulin biosynthesis at pancreatic level and are responsible for up to 70% of insulin secretion following a meal. 14, 15 Since after secretion GLP-1 and GIP are rapidly degraded by DPP-IV, 16 the inhibition of this enzyme improves the glucose tolerance in diabetic patients by enhancing the insulinotropic effects of GLP-1 17 and lowers blood glucose via stimulation of insulin and inhibition of glucagon. For this reason DPP-IV inhibitors have emerged as a new class of oral antidiabetic agents, 18 with excellent therapeutic potentials in the management of type 2 diabetes. 11, 19 The synthetic DPP-IV inhibitors sitagliptin and vildagliptin are currently the most widely investigated new drugs for the treatment of type 2 diabetes. 20 Interestingly, some food proteins appear to be sources of DPP-IV inhibitory peptides, which may be released from their sequences by enzymatic hydrolysis. For example, DPP-IV inhibitory peptides have been isolated and characterized from the proteins of cow milk, 21 bovine proteins, 22, 23 goat milk, 24 silver carp, 25 tuna, 26 salmon, 27 rice, 28 black bean, 29 and amaranth. 30 Owing to our interest for the role of plant proteins and peptides in the prevention of hypercholesterolemia and hyperglycemia, in the past few years, we have collected some bioactive peptides from soy (Soy 1−3) and lupin proteins (Lup 1−3) and investigated their biological activities (Table 1) . Soy 1 (IAVPTGVA) corresponds to position 142−149 of glycinin (UniProtK P04776.2) and modulates cholesterol and glucose biosyntheses in HepG2 cells. 6, 31, 32 Soy 2 (YVVNPDNDEN) corresponds to position 232−241 of the α subunit of β-conglycinin (UNIProtKB P13916), whereas Soy 3 (YVVNPDNNEN) corresponds to positions 310−319 of the α′ subunit of β-conglycinin (UNIProtKB P11827). Both are able to inhibit the activity of 3-hydroxymethylglutarylCoA reductase (HMGCoAR) and to modulate cholesterol biosynthesis in HepG2 cells. 33 Interestingly, an investigation in Caco2 cells has shown that they are potentially absorbed at intestine level. 34 Lup 1 (LTFPGSAED), Lup 2 (LILPKHSDAD), and Lup 3 (GQEQSHQDEGVIVR) correspond to positions 484− 492, 235−244, and 362−375, respectively, of β-conglutin (UniProtKB Q53HY0.2), a 7S storage protein. Using monolayers of Caco2 cells grown in bicameral system, we have recently demonstrated that these lupin peptides are transferred from the apical to the basolateral chamber and that the basolateral solution inhibits the activity of HMGCoAR and modulate cholesterol metabolism in HepG2 cells. 35, 36 BIOPEP (www.uwm.edu.pI/biochemia) 37 is an open access database enabling to hypothesize the potential biological activities of peptides based on the presence of specific amino acid sequences. A screening of the structures of these peptides with BIOPEP suggested that their structures were compatible with a potential DPP-IV inhibitory activity. In case of Soy 1 the sequences were VA, VP, IA, AV, GV, PT, TG; for Soy 2 they were VV, NP, DN, ND, VN, YV; for Soy 3 they were VV, NP, DN, NE, NN, VN, YV; for Lup 1 they were FP, AE, LT, PG, TF; for Lup 2 they were LP, AD, HS, IL, KH, LI, PK; and for Lup 3 they were GQ, VR, EG, GV, QD, QE, QS, SH, VI. It was thus decided to evaluate experimentally their potential inhibitory activity using a commercial in vitro bioassay against human recombinant DPP-IV. Subsequently, the interaction of two active peptides and an inactive one with the enzyme was investigated employing an in silico molecular model and scoring approach. The present work describes the results of these investigations.
■ MATERIALS AND METHODS
Materials. Tris-HCl, ethylenediaminetetraacetic acid (EDTA), and NaCl were from Sigma-Aldrich (St. Louis, MO, USA). The peptides Soy 1−3 and Lup 1−3 (Table 1) were synthesized by the company PRIMM (Milan, Italy) with >95% purity, assessed by HPLC.
DPP-IV Activity Assay. The DPP-IV enzyme and the substrate solution (5 mM H-Gly-Pro-AMC) were provided by Cayman Chemicals (Michigan, USA). The experiments were carried out in triplicate in a half volume 96 well solid plate (white). Each reaction (50 μL) was prepared adding the reagents in a microcentrifuge tube in the following order: 1 × assay buffer [20 mM Tris-HCl, pH 8.0, containing 100 mM NaCl, and 1 mM EDTA] (30 μL), 100 μM of each soy and lupin peptide [Soy 1−3 or Lup 1−3] or vehicle (10 μL), and finally the DPP-IV enzyme (10 μL). Subsequently, the samples were mixed and 50 μL of each reaction was transferred in each plate well. Each reaction was started by adding 50 μL of substrate solution to each well and incubated at 37°C for 30 min. Fluorescence signals were measured using the Synergy H1 fluorescent plate reader from Biotek (excitation and emission wavelengths 360 and 465 nm, respectively). In order to build the dose-inhibition curves of the active peptides Soy 1 and Lup 1, concentrations in the range 10−1000 μM were tested using the same procedure described above.
Statistically Analysis. Statistical analyses were carried out by Oneway ANOVA using Graphpad Prism 6 (Graphpad, La Jolla, CA, USA) followed by Dunnett's test. Values were expressed as means ± SEM; P-values < 0.05 were considered to be significant.
Computational Methods. By applying a computational strategy already adopted in a previous study, 33 two active peptides and an inactive one (i.e., Soy 1, Lup 1, and Lup 2) were built in canonical α-helix by using the Peptide Builder function of the VEGA suite of programs 38 and their conformational profiles were explored by a MonteCarlo procedure, which produced 10 000 conformers by randomly rotating the backbone torsions only. The obtained geometries were then clustered according to their similarity to discard redundant ones; here, two conformations were considered as nonredundant when they differed by more than 60 degrees in at least one backbone torsion angle. For each cluster, the lowest energy structure was collected and memorized.
Among the resolved human DPP-IV structures, the study involved the complex between the enzyme and the long-acting inhibitor omarigliptin (PDB ID: 4PNZ) chosen due to its very high resolution. 39 After deleting water molecules, ions, and crystallization additives, the selected dimer bound to omarigliptin was completed by adding the hydrogen atoms and then optimized by keeping fixed the backbone atoms to preserve the resolved folding. The inhibitor was finally deleted and the obtained protein structure underwent the following docking simulations.
Docking simulations were carried out by using PLANTS and involved the 20 lowest energy conformations as derived by the previous MonteCarlo analysis in order to minimize the biasing effects of the starting conformation on the obtained results. 40 In detail, the search was focused on a 12.0 Å radius sphere around the bound omarigliptin thus including the entire binding cavity. PLANTS was used with default settings and without geometric constraints, speed 1 was used and 5 poses were generated for each conformer and scored by using the PLP function. The obtained poses were evaluated by considering both the docking scores and the conformational energies of the docked conformers. The best generated poses was then minimized keeping fixed all atoms inside a 12.0 Å radius sphere around the bound peptide.
The computed best DPP-IV/Soy 1 complex was neutralized, inserted into a 100 Å side cubic box containing about 19000 water molecules and, after a preliminary minimization, underwent 10 ns MD run by using NAMD with the same characteristics already described in a previous study. 33 ■ RESULTS Biochemical Evaluation of the Inhibition of DPP-IV Activity. Figure 1 shows the results of the experiments aimed to evaluate the inhibitory activity of soybean and lupin peptides against recombinant DPP-IV using H-Gly-Pro-AMC as substrate. The enzymatic reaction was monitored measuring the fluorescence signals (465 nm) due to the release of free Figure 1 . DPP-IV inhibitory activities of Soy 1−3 and Lup 1−3. Each peptide was tested at the final concentration of 100 μM, in parallel with the positive control, sitagliptin (0.1 μM). Bars represent the averages ± SEM of 3 independent experiments in triplicate. ns: not significant and *** P < 0.0001 versus the enzyme activity.
AMC group after the cleavage of the peptide H-Gly-Pro catalyzed by DPP-IV. Each peptide was screened at the final concentration of 100 μM, in parallel with sitagliptin as positive control (0.1 μM). Two peptides showed inhibitory activity: Soy 1 reduced the DPP-IV activity by 46% and Lup 1 by 35%. On the contrary, Soy 2, Soy 3, Lup 2, and Lup 3 were inactive, whereas the positive control sitagliptin inhibited the DPP-IV activity by 88% (Figure 1 ). Dose−response curves were then built for the two active peptides (Figure 2 ): Soy 1 displayed the highest inhibitory activity with an estimated IC 50 value of 106 μM, whereas Lup 1 was less efficient, since its IC 50 was 228 μM.
Molecular Modeling Investigation.
With the objective of revealing the key interactions elicited by the simulated peptides and better rationalizing their different behavior, a molecular docking study was undertaken. Even though performed a posteriori and without a predictive character, these results are useful to delve into the recognition processes between DPP-IV and peptide inhibitors and as such they may be useful when screening novel peptide libraries. Figure 3 shows the putative complex between Soy 1 and DPP-IV revealing the key ionic interactions, which involve both peptide charged termini and seem to play a largely predominant role. In detail, the amino terminus is engaged in a double salt bridge involving Glu205 and Glu206, while the carboxyl terminus stabilizes an ion-pair with Arg358. The key role of these ionic contacts is confirmed by the comparison of the computed pose of Soy 1 with the crystallographic pose of omarigliptin shown in Figure 4 , which highlights the perfect matching of the Soy 1 N-terminus with the amino group of omarigliptin as well as of the Soy 1 Cterminus with the sulphonyl group of omarigliptin. Apart from Thr5, which reinforces the contacts elicited by the ammonium head by approaching Glu205, the remaining part of the peptide appears to be marginally involved in the complex stabilization. In fact, the central residues might even play a negative role, since peptide apolar residues are seen to contact protein polar residues as in the case of Pro4, which unfittingly approaches Glu206 and Ser209. Moreover, Soy 1 does not contain any aromatic side-chains able to elicit π−π stacking interactions with the numerous aromatic residues lining the enzyme cavity.
This pattern of key interactions can easily rationalize the different inhibitory activities observed for the other simulated peptides. In detail, the marked difference in the inhibition activity between Lup 2 and Lup 1 seems to be mostly attributable to the interfering effect of the central Lys5 residue in Lup 2, which stabilizes the ionic contacts normally involving the amino terminus, which is therefore constrained to detrimentally approach Arg125. In detail, the carboxyl terminus of both Lup 2 and Lup 1 peptides interacts with Arg358 and Arg356 and is engaged in an extended ionic network also involving the side-chain of the C-terminal residue (Asp10 in Lup 2 and Asp9 in Lup 1) and Arg429. As mentioned above, the greatest differences concern the contacts stabilized by the amino terminus, since it elicits the already described ion-pairs with Glu205 and Glu206 in the active peptide Lup 1, whereas in the inactive Lup 2 peptide it is replaced by Lys5 and is confined to a more lateral pose, where it approaches Arg125, while contacting Glu205. In the putative complexes of both Lup 2 and Lup 1, the central residues seem to play a relevant role. In detail, the negatively charged residue in the C-terminal segment of both peptides (Asp8 of Lup 2 and Glu8 of Lup 1) are involved in the ionic network stabilized around the carboxyl terminus as explained above. Moreover, Lup 1 includes an aromatic residue (Phe3) engaged in a rich set of π−π stacking involving Tyr547, Trp629, and His740. The key role played by the ionic interactions is further confirmed by the encouraging agreement found between the measured IC 50 values and the computed APBS scores which specifically accounts for electrostatic interactions (−75.23, −49.14, and −13.38 kJ/ mol for Soy 1, Lup 1, and Lup 2, respectively).
In order to substantiate the docking results, a MD simulation involving the computed DPP-IV/Soy1 complex was carried out. As shown in Table 2 , such a simulation confirmed the marked stability of the complex, which appears to be further reinforced by the stabilization of additional contacts during the simulation time. Table 2 reports the initial, final, and average distance values for some key interactions and confirms the clear stability of the already mentioned ion-pairs, which are stably retained throughout the MD run. In detail, Table 2 reveals the marked stability of the ionic contacts involving Asp205, Asp206, and Arg358, while the salt bridge with Arg356 is progressively lost to minimize the repulsion with the close Arg358 residue, which indeed approaches Glu403 at the end of simulation and forms an extended ionic network also involving Glu361, Arg382, and Asp588.
Notably, Table 2 shows that the central residues, which are not engaged in clear interactions in the starting structure, gain at least two key H-bonds involving the hydroxyl function of Ser5 with Ser209 and the backbone atoms of Gly6 with Tyr588. Besides a clear rearrangement of the DPP-IV residues involved in the key contacts, the MD simulations reveals that the stabilization of these additional residues is also due to conformational shifts of the Soy 1 structure, which assumes more extended geometries due to turn-coil transitions. The progressive stabilization of the simulated complex found a convincing confirmation in the dynamic profile of the ChemPLP score function as computed during the MD run by the ReScore+ tool.
41 Figure 5 clearly shows that after an initial increase, the score function progressively lowers to confirm a substantial strengthening of the stabilizing contacts with a gain of about 20 kcal/mol at the end of the simulation.
Taken together, the docking results allow some general considerations. Ionic interactions stabilized by charged termini play a clearly crucial role even though their contribution is easily saturating and the stabilizing effect of the additional ionized side chains appears to be almost negligible, if not even negative (as seen for Lys5 in Lup 2). This effect can be explained by considering the closeness between the cluster of protein negatively charged residues (i.e., Glu205 and Glu206) and that of positively charged residues (i.e., Arg358 and Arg356) and more generally the richness of ionized residues lining the enzyme cavity. In this way, the additional ionized side chains tend to interfere with the crucial contacts elicited by charged termini rather than playing a concrete stabilizing role.
Clearly, such an interfering effect is an indirect consequence of the molecular size of the simulated peptides, which are excessively bulky, when considering that the enzyme cavity and the key stabilizing contacts are elicited by the two terminal groups, thus suggesting that the entire peptide should be 
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Article accommodated within the catalytic cavity that is in fact arranged to accommodate dipeptide substrates. Together with the sequence, also the length, combined with the necessary involvement of both charged termini, can thus explain the inactivity of the other (nonsimulated) longer peptides (i.e., Soy 2, Soy 3, and Lup 3) and can surely contribute to the inactivity of Lup 2. Finally, the nonionized central residues of the simulated peptides appears to play very negligible roles and probably only Phe3 of Lup 1, which is engaged in π−π stacking interactions, should have a concrete stabilizing function thus differentiating Lup 1 from the other considered ligands.
■ DISCUSSION
Although the health benefits of soy and lupin protein consumption are well-known, particularly in the area of cholesterol reduction, hypertension, and hyperglycemia prevention, this is the first study providing preliminary evidence that at least some peptides from soy and lupin protein may be able to inhibit the DPP-IV activity. This is an original contribution, since the hypoglycemic activity of soy protein has been previously explained with an improvement of glucose uptake in muscle cells 7 and hepatocytes, 6 and that of lupin protein by an insulin-like mechanism. 10 Some years ago, a patent 42 had reported the structures of 21 peptides capable of inhibiting DPP-IV activity. They have a hydrophobic character, a length varying from 2 to 8 amino acid residues, and contain a Pro residue within their sequences, which is located at the first, second, third, or fourth N-terminal position. Besides, the Pro residue is flanked by Leu, Val, Phe, Ala, and Gly. Indeed, our data are consistent with this patent. In fact, as the fourth N-terminal residue, the active peptides Soy 1 and Lup 1 comprise a Pro, which is flanked by a Val residue in Soy 1 and by a Phe residue in Lup 1. Moreover, these peptides are mostly composed of hydrophobic amino acid residues, such as Ala, Gly, Ile, Leu, and Pro. The inactive peptides, i.e., Soy 2, Soy 3, Lup 2, and Lup 3, are probably too long, since they contain 10−14 amino acid residues. In addition, some of them do not respect the structural features indicated above: Soy 2 and Soy 3 comprise a Pro residue unfavorably located as fifth N-terminal residue and not flanked by any hydrophobic amino acid residue, whereas Lup 3 does not contain any Pro residue.
Finally, it is useful to compare the DPP-IV inhibitory activities of our peptides with other food peptides, such as those derived from silver carp protein, 25 Atlantic salmon skin gelatin, 27 bovine meat, 22 and goat milk protein. 24 Two peptides (PPL and PPG) with moderate activity have been identified in bovine meat protein hydrolyzates with IC50 390.1 μM and 2252.7 μM, respectively, using human recombinant DPP-IV. 22 Four peptides (AGPPGPSG, APGPAGP, LPIIDI, and ALAPSTM) have been identified from the hydrolysis of silver carp protein; 25 out of them LPIIDI and APGPAGP showed the highest DPP-IV inhibitory activity, with IC 50 values equal to 105.4 and 229.1 μM, respectively, using porcine DPP-IV, 25 which are similar to those of Soy 1 and Lup 1. On the contrary, the peptides GPAG and GPGA from Atlantic salmon skin gelatin 27 and INNQFLPYPY from goat milk 24 appeared to be more active, showing the following IC 50 inhibitory values: GPAG IC 50 = 49.6 μM, GPGA IC 50 = 41.9 μM, and INNQFLPYPY IC 50 = 40.1 μM (on porcine DPP-IV).
When discussing the relevance of the activity of any food component, a general issue is the bioavailability. In this case, the situation is favorable for Lup 1, since a very recent paper has already demonstrated that this peptide is able to cross a monolayer of differentiated human enterocytes (CaCo-2 cells), 35 an in vitro model of gastrointestinal absorption. Work is in progress in our lab to assess the bioavailability of Soy 1. 
Notes
The authors declare no competing financial interest.
■ ABBREVIATIONS USED
DPP-IV, dipeptidyl peptidase IV; GLP-1, glucagon-like peptide 1; GIP, glucose-dependent insulinotropic polypetide; AMC, aminomethylcoumarin; EDTA, ethylenediaminetetraacetic acid
